Search

Your search keyword '"Kamboj, Amrit K."' showing total 579 results
Start Over Author "Kamboj, Amrit K."
579 results on '"Kamboj, Amrit K."'

54. Clinical Outcomes After Endoscopic Management of Low-Risk and High-Risk T1a Esophageal Adenocarcinoma: A Multicenter Study.

Author

Kamboj, Amrit K., Goyal, Rohit, Vantanasiri, Kornpong, Sachdeva, Karan, Passe, Melissa, Lansing, Ramona, Garg, Nikita, Chandi, Paras S., Ramirez, Francisco C., Kahn, Allon, Fukami, Norio, Wolfsen, Herbert C., Krishna, Murli, Pai, Rish K., Hagen, Catherine, Hee Eun Lee, Wang, Kenneth K., Leggett, Cadman L., and Iyer, Prasad G.

Subjects
*ENDOSCOPIC surgery, *BARRETT'S esophagus, *TREATMENT effectiveness, *ADENOCARCINOMA, *OVERALL survival
Abstract

INTRODUCTION: Endoscopic eradication therapy (EET) is standard of care for T1a esophageal adenocarcinoma (EAC). However, data on outcomes in high-risk T1a EAC are limited. We assessed and compared outcomes after EET of low-risk and high-risk T1a EAC, including intraluminal EAC recurrence, extraesophageal metastases, and overall survival. METHODS: Patients who underwent EET for T1a EAC at 3 referral Barrett's esophagus endotherapy units between 1996 and 2022 were included. Patients with submucosal invasion, positive deep margins, or metastases at initial diagnosis were excluded. High-risk T1a EAC was defined as T1a EAC with poor differentiation and/or lymphovascular invasion, with low-risk disease being defined without these features. All pathology was systematically assessed by expert gastrointestinal pathologists. Baseline and follow-up endoscopy and pathology data were abstracted. Time-to-event analyses were performed to compare outcomes between groups. RESULTS: One hundred eighty-eight patients with T1a EAC were included (high risk, n 5 45; low risk, n 5 143) with a median age of 70 years, and 84% were men. Groups were comparable for age, sex, Barrett's esophagus length, lesion size, and EET technique. Rates of delayed extraesophageal metastases (11.1% vs 1.4%) were significantly higher in the high-risk group (P 5 0.02). There was no significant difference in the rates of intraluminal EAC recurrence (P 5 0.79) and overall survival (P 5 0.73) between the 2 groups. DISCUSSION: Patients with high-risk T1a EAC undergoing successful EET had a substantially higher rate of extraesophageal metastases compared with those with low-risk T1a EAC on long-term follow-up. These data should be factored into discussions with patients while selecting treatment approaches. Additional prospective data in this area are critical. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

60. sj-docx-1-tag-10.1177_17562848231168237 – Supplemental material for The natural history of histological changes in microscopic colitis

Author

Sehgal, Kanika, Tome, June, Kamboj, Amrit K., Dierkhising, Ross A., Pardi, Darrell S., and Khanna, Sahil

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tag-10.1177_17562848231168237 for The natural history of histological changes in microscopic colitis by Kanika Sehgal, June Tome, Amrit K. Kamboj, Ross A. Dierkhising, Darrell S. Pardi and Sahil Khanna in Therapeutic Advances in Gastroenterology

Published
2023
Full Text
View/download PDF

78. Authors' Reply to Letter—Role of Prokinetics in Ineffective Esophageal Motility: A Call for Broader Consideration and Future Innovations.

Author

Kamboj, Amrit K., Katzka, David A., Vela, Marcelo F., Yadlapati, Rena, and Ravi, Karthik

Subjects
*ESOPHAGEAL motility disorders, *ESOPHAGEAL motility, *DIGESTIVE system diseases, *GASTROESOPHAGEAL reflux, *ESOPHAGUS diseases, *CHEST pain, *METOCLOPRAMIDE
Abstract

The article discusses the role of prokinetics in ineffective esophageal motility (IEM) and the need for further research to understand their potential benefits. While some studies show promise in using prokinetic agents like erythromycin and azithromycin, limitations such as small sample sizes and inconsistent outcome measures exist. The authors suggest tailoring testing and therapy based on predominant symptoms like reflux, dysphagia, or chest pain, and emphasize the importance of lifestyle modifications before considering prokinetics. Future high-quality studies with long-term follow-up are needed to determine the therapeutic efficacy of prokinetics in patients with IEM. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results